Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,548.17
-13.1079-0.84%
Number of Gainers:1
Number of Losers:6
Number of Flat:- -
PE:- -
High:1,569.66
Open:1,563.81
Low:1,545.55
Close:1,561.28
Volume:46.94M
Turnover:4.25B
Market Cap:1.61T
Float Cap:1.55T

Loading ...

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

Pfizer CEO Bourla to Speak at Morgan Stanley Global Healthcare Conference Webcast

Reuters
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08

Structure Therapeutics Releases Amylin and GLP-1 Program Presentation

Reuters
·
Sep 08

Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671

Reuters
·
Sep 08

Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026

THOMSON REUTERS
·
Sep 08